IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Dr. Faz Chowdhury, Chairman and CEO of Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing and commercializing affordable diagnostic and digital tools for chronic disease management.
Throughout the interview, Chowdhury provided an introduction to Nemaura Medical and discussed its business model.
“Nemaura Medical was founded just over a decade back, and, over that period of time, we’ve been focused on developing a body-worn sensor designed for both consumer and medical applications in the diabetes space,” Chowdhury said. “We use the sensor to look at insight you otherwise could not gauge just by using existing technologies – taking a drop of blood and putting it on a strip, for example. … It has taken us a good part of the 10 years to develop the technical aspects of the product, get the clinical studies done and get regulatory approvals in Europe. Now, we are already commercializing product in the U.K., and we are looking at launching in other places in Europe and then into the U.S.”
“If you look at the market, there are something like half a billion people around the world with diabetes. For the U.K. market, we have around 4 million people [with diabetes]; in the U.S., you have about 30 million people,” he continued. “Our focus at the moment has been entirely on the U.K. market, because the product is approved in Europe. We’ve been working with our licensee to supply sensors. Their first order was for a couple hundred thousand sensors and a few thousand devices, with rolling forecasts of up to another couple million sensors over the coming two years. However, in the U.K., that doesn’t include a second route to market.”
“There are a number of medications that are supplied to people with type II diabetes with a view to helping them improve control over their sugar levels. The issue is that … if they’ve got no way of really measuring the benefit, you’ve got no idea of what the outcome really is,” Chowdhury added. “In this case, we have a license agreement whereby our licensee will actually be supplying the sensors free of charge with those medicines – and those medicines are reimbursed. … There are over 2 million prescriptions written every month in the U.K. and Germany alone. … The number of devices and sensors and, therefore, the revenue projections are quite significant. We are expecting to get into that second strand of commercialization with the combination of the sensor and the drug by the end of the year.”
Join IBN’s Stuart Smith and Dr. Faz Chowdhury, Chairman and CEO of Nemaura Medical Inc. (NASDAQ: NMRD), to learn more about the company’s seasoned management team, as well as its recent milestones and its goals for the balance of 2022 and beyond.
To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine.
About Nemaura Medical Inc.
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™.
sugarBEAT®, a CE mark-approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service in the U.S. as a general wellness product as part of its BEAT® diabetes program that is currently undergoing pilot studies.
Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being.
For more information, visit the company’s website at www.NemauraMedical.com.
IBN consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its Investor Brand Platform, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.